Isoangustone A dose-dependently decreased DNA synthesis and induced G1 phase arrest in human prostate and mouse breast cancer cells, reduced the levels of CDK2 and CDK4 as well as cyclin A and cyclin D1 proteins, and also induced a decrease in CDK2 activity. The gene discussed is CDK2; the disease is breast carcinoma.